| Date: | 2010-09-03 |
| Company: | Lumavita (Switzerland) |
| Investors: | |
| Amount: | 11m (€8m) |
| Planned use: | Lumavita AG, the Basel biopharmaceutical company specializing in novel anti-infectives for Women’s Health has raised approximately CHF 11m (€8m) from its current investors. T his financing will enable the company to continue the development of its two products LMV-601 and LMV-602, and in particular will allow the completion of some first proof-of-concept studies in human in 2011. |
| Other: |
